Sarcopenia Common, Potentially Life-Threatening in Nondialysis CKD
The prevalence of CKD-related sarcopenia may be higher than ageing-related sarcopenia.
Imaging
FDA Approves Tracer That Improves Detection of Advanced Prostate Cancer
Tracer is injected into the bloodstream and lights up metastatic prostate cancer cells during PET scan
COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
MRI Prior to Prostate Cancer Active Surveillance May Reduce Dropout Rate
Findings from a recent study suggest that the use of magnetic resonance imaging could lead to more patients being considered unsuitable for active surveillance, according to investigators.
Guidelines Provided for Unilateral Lymphadenopathy After COVID-19 Vaccination
In most clinical settings, ipsilateral UAL after recent COVID-19 vaccination is benign finding; clinical follow-up recommended
MRI May Have a Role in Community-Based Prostate Cancer Screening
Biparametric magnetic resonance imaging may offer advantages over PSA testing and ultrasonography by detecting more clinically significant prostate cancers without increasing the number of men advised to undergo prostate biopsies or overdiagnosed with clinically insignificant cancers.
Periprostatic Fat Possibly Prognostic for Men on PCa Active Surveillance
In a study of patients on active surveillance, men with greater periprostatic fat had shorter prostate cancer progression-free survival.
Multiparametric MRI Frequently Underestimates Prostate Tumor Size
As radiologic tumor size and PI-RADS version 2 score decreased, the degree to which pathologic tumor size is underestimated increased, investigators reported.
Inappropriate Imaging of Low-Risk Prostate Cancer Patients Continues
Use of computed tomography and bone scans in low-risk prostate cancer cases has been in decline, but doctors continue to order these imaging modalities despite professional guidelines that do not recommend such use.
FDA Approves PSMA-Targeted Drug for PET Imaging of Prostate Cancer
Ga 68 PSMA-11 PET can detect sites of local recurrence or metastasis in patients with biochemical evidence of recurrent prostate cancer.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...